Related Experiment Video
Updated: Sep 1, 2025
04:16
Author Spotlight: Advancing Lung Transplant Immunology Through Intravital Imaging
Published on: April 19, 2024
1.2K
Biomarkers for Chronic Lung Allograft Dysfunction: Ready for Prime Time?
Stijn E Verleden1,2,3, Jeroen M H Hendriks1,2, Patrick Lauwers1,2
1Antwerp Surgical Training, Anatomy and Research Centre (ASTARC), Department of Thoracic and Vascular Surgery, University of Antwerp, Wilrijk, Belgium.
Transplantation
|August 18, 2022
Summary
Identifying biomarkers for chronic lung allograft dysfunction (CLAD) is crucial for lung transplant success. Combining clinical data with tissue, lavage, and blood markers aids early CLAD detection and improves patient prognosis.
Area of Science:
- Transplantation immunology
- Pulmonary medicine
- Biomarker discovery
Background:
- Chronic lung allograft dysfunction (CLAD) significantly hinders lung transplant outcomes.
- Accurate CLAD detection and prognostication require improved diagnostic tools.
- Current clinical methods for CLAD assessment have limitations.
Purpose of the Study:
- To review the current state of biomarker research for CLAD.
- To highlight progress in identifying radiological, tissue, bronchoalveolar lavage, and blood biomarkers.
- To discuss the potential of combined biomarker strategies for early CLAD detection.
Main Methods:
- Review of recent literature on CLAD biomarkers.
- Focus on radiological imaging, peripheral tissue analysis, bronchoalveolar lavage fluid, and blood markers.
- Synthesis of findings regarding biomarker utility in CLAD diagnosis and prognosis.
Main Results:
- Significant advancements have been made in identifying various CLAD biomarkers.
- Radiological and biological markers show promise for earlier detection.
- No single biomarker is sufficient; a multimodal approach is needed.
Conclusions:
- Biomarker research is vital for improving lung transplant outcomes.
- Combining clinical data with multi-source biomarkers (tissue, lavage, blood) is key.
- Early CLAD identification through integrated biomarker strategies can enhance patient prognosis.
